EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lexeo Therapeutics's enterprise value is $384.48 Mil.
Lexeo Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Lexeo Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Lexeo Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 4 years, the highest EV-to-Revenue of Lexeo Therapeutics was 755.71. The lowest was 414.44. And the median was 634.14.
LXEO's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.86 * Ranked among companies with meaningful EV-to-Revenue only.
The historical data trend for Lexeo Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lexeo Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Lexeo Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexeo Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Lexeo Therapeutics's EV-to-Revenue falls into.
Lexeo Therapeutics's current Enterprise Value is $384.48 Mil.
Lexeo Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics's share price for today is $17.25.
Lexeo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Lexeo Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexeo Therapeutics (Lexeo Therapeutics) Business Description
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LXEO has been successfully added to your 